SenesTech revenue crosses $1m for first time as SNES stock surges

SenesTech, Inc. has crossed the $1 million quarterly revenue threshold for the first time, reporting preliminary third-quarter sales of approximately $1.1 million as its direct-to-consumer and business-to-business strategy begins producing faster growth. Revenue increased roughly 40% from the second quarter and approximately 55% from the same period last year, setting a second consecutive quarterly record for the rodent fertility-control company. Management says e-commerce, subscription revenue and growing commercial adoption of its Evolve products drove the improvement, while many of the transition costs associated with restructuring its sales model were incurred earlier in the year. Investors responded aggressively, with SNES shares trading around $0.87 near midday Thursday, approximately 36% above Wednesday’s $0.64 close on extraordinarily heavy volume.

The milestone is significant because SenesTech remains a very small company whose annual revenue was only $2.22 million in 2025. A $1.1 million quarter therefore represents a meaningful acceleration rather than an incremental improvement, particularly after second-quarter revenue totaled approximately $770,000. The larger question for shareholders is whether the commercial momentum can continue quickly enough to offset ongoing operating losses and reduce the company’s dependence on outside financing. SenesTech ended June with approximately $5.1 million of cash, but management has previously acknowledged that additional capital will likely be required before the business reaches profitability and positive cash flow.

SenesTech’s record $1.1 million quarter shows its commercial strategy is gaining momentum

Preliminary third-quarter revenue of approximately $1.1 million compares with $770,000 during the second quarter, giving SenesTech sequential growth of roughly 40%. The company also estimates revenue increased approximately 55% from the third quarter of 2025. Final results remain subject to normal quarter-end procedures, and SenesTech expects to publish its complete third-quarter financial statements during the week of November 9.

The growth follows an already strong second quarter. Second-quarter revenue increased 23% year over year and approximately 56% from the first quarter, while gross margin reached a company record of 73.6%. That margin performance is particularly important because it suggests SenesTech is not simply generating additional sales through heavily discounted products or uneconomic customer acquisition. Higher-margin revenue creates a more credible pathway toward covering the fixed sales, research and administrative costs that currently keep the company unprofitable.

Management attributes much of the improvement to taking greater control over e-commerce. SenesTech brought its Amazon and Shopify operations directly in-house, giving the company more control over pricing, customer relationships, marketing data and subscriptions. In the second quarter, total e-commerce revenue increased 186% sequentially, while the active online subscriber base more than doubled compared with the first quarter.

That momentum continued into July, when e-commerce revenue reached a record $245,000, up 19% from June, while subscription revenue increased 22% sequentially to approximately $53,000. Subscription growth matters because recurring purchases can improve revenue visibility and reduce the need to continually reacquire the same customers through paid marketing.

Chief Executive Officer Michael Edell said the third-quarter performance reflects progress across the commercial model SenesTech has spent much of 2026 building. Management expects the final quarterly numbers to show higher subscription revenue alongside improving business-to-business traction, while arguing that several investments and transition expenses incurred earlier in the year are now beginning to move behind the company.

Evolve is turning rodent fertility control into SenesTech’s primary growth engine

SenesTech’s strategy is unusual within pest management because its flagship products target rodent reproduction rather than relying solely on poisons designed to kill existing populations. Evolve Rat and Evolve Mouse are fertility-control products that can be incorporated into broader pest-management programs, while ContraPest provides another reproduction-control approach.

The company argues that reducing reproduction can complement conventional traps and rodenticides by addressing the rate at which populations replace themselves. SenesTech is targeting consumers as well as professional pest-control operators, agriculture, municipalities, retail customers and other commercial users, giving the product line several possible distribution channels rather than dependence on a single end market.

Distribution has gradually expanded. SenesTech previously signed Bradley Caldwell, Inc. as a U.S. distributor, giving the company access to a network serving more than 8,000 farm, ranch, hardware and pet-supply dealers. International expansion has included distribution into Bermuda, while the company has continued targeting agricultural and municipal applications where rodent populations can create recurring economic and sanitation problems.

SenesTech has also been publishing results from real-world deployments. A six-month program in Swampscott, Massachusetts, using Evolve Rat as part of an integrated pest-management strategy produced a reported 43% reduction in rodent activity. While individual deployments do not by themselves prove broad commercial adoption, successful municipal and agricultural case studies can help SenesTech convince professional buyers that fertility control belongs alongside traditional pest-management methods.

The opportunity remains dependent on education. Traditional rodenticides are already widely understood by both consumers and professional pest-control operators, while fertility control represents a newer category that can require customers to change established practices. That means SenesTech must continue spending on marketing, sales staff and demonstrations even as management simultaneously tries to reduce operating losses.

Record gross margin is encouraging, but SenesTech still loses considerably more than it generates in sales

The most important counterweight to the revenue growth is SenesTech’s cost structure. The company reported a second-quarter net loss of approximately $1.83 million despite generating only $770,000 of revenue. For the first six months of 2026, the net loss reached approximately $3.9 million, compared with about $3.3 million during the same period last year.

Operating cash consumption remains similarly important. SenesTech used approximately $3.6 million of cash in operating activities during the first half of 2026, up from $2.7 million in the comparable 2025 period. Cash and equivalents declined to roughly $5.08 million by June 30 from $7.58 million at the end of 2025, although a maturing short-term investment partially supported overall liquidity during the period.

Management has explicitly acknowledged the funding challenge. In its second-quarter filing, SenesTech said existing cash combined with anticipated revenue was expected to support current operations through the end of the first quarter of 2027. The company also stated that additional financing will be needed to fund operating losses before it reaches sufficient revenue and margins to become profitable and generate positive cash flow.

SenesTech maintains an at-the-market equity facility that provides one possible source of financing. As of June 30, approximately $7.3 million of capacity remained available under that program. Selling shares through the facility could strengthen liquidity, but it would also dilute existing shareholders, particularly if capital is raised while SNES trades near historically depressed levels.

That financing tension is why the accelerating revenue trend matters so much. At the second-quarter 73.6% gross margin, each incremental dollar of revenue theoretically contributes substantially more toward covering operating expenses than it did when margins were weaker. If sales continue expanding at the pace seen in the second and third quarters while gross margins remain elevated, operating losses could narrow even without dramatic reductions in spending.

However, investors will need actual third-quarter expense and cash-flow figures before concluding that the economics have materially changed. Preliminary revenue alone does not reveal marketing costs, customer-acquisition spending, compensation expenses or whether cash consumption improved during the quarter.

SNES stock explodes higher, but the long-term chart shows how much confidence SenesTech has lost

The immediate stock reaction has been dramatic. SNES traded near $0.87 around midday October 15, up approximately 36% from its $0.64 previous close. Trading volume exceeded 44 million shares by shortly after noon, compared with an average daily volume measured in only tens of thousands of shares during recent periods.

That surge needs substantial context. SenesTech had touched a 52-week low near $0.61 only two days earlier, while its 52-week high stands around $4.19. Even after Thursday’s rally, the stock remains dramatically below where it traded a year ago.

At approximately $0.87, SenesTech’s market capitalization was around $4.7 million based on roughly 5.4 million shares outstanding. That figure is notable because it remains below the $5.1 million of cash reported at the end of June, although comparing market capitalization directly with an older cash balance can be misleading because the company continues using cash to fund operations.

The stock’s tiny float also helps explain the magnitude of Thursday’s reaction. ChartExchange estimates the freely tradable float at approximately four million shares, meaning unusually high buying interest can create extremely large percentage moves in either direction. The explosive volume therefore shows substantial investor attention but should not automatically be interpreted as evidence that the market has permanently repriced the company’s fundamentals.

The more durable investment case depends on whether SenesTech can convert its recent revenue acceleration into lower losses and a longer cash runway. Crossing $1 million in quarterly revenue is meaningful for a company whose entire 2025 revenue was only $2.22 million, but annualizing one record quarter would still leave the business small relative to its operating expense base.

The November financial report will therefore matter much more than Thursday’s share-price spike. Investors need confirmation of the $1.1 million preliminary revenue figure, updated gross margin, subscription trends, operating expenses and the September cash balance. A third consecutive quarter of accelerating revenue accompanied by narrower losses would provide much stronger evidence that SenesTech’s turnaround is becoming structural.

Key takeaways on SenesTech’s record third-quarter revenue and SNES stock rally

• SenesTech expects preliminary third-quarter revenue of approximately $1.1 million, the first quarter above the $1 million threshold in company history.
• Revenue increased roughly 55% year over year and 40% sequentially, extending the acceleration seen during the second quarter.
• E-commerce, subscriptions and growing business-to-business adoption are becoming the primary drivers of the company’s commercial expansion.
• Second-quarter gross margin reached a record 73.6%, an encouraging sign that higher revenue may provide stronger operating leverage.
• SenesTech still reported a $1.83 million second-quarter net loss and used approximately $3.6 million of operating cash during the first half.
• Cash stood at approximately $5.1 million on June 30, while management has said additional financing will likely be required before profitability.
• SNES surged roughly 36% around midday Thursday on exceptionally heavy trading volume following the preliminary revenue announcement.
• The stock remains far below its 52-week high despite the rally, underscoring the market’s previous concerns around losses, dilution and commercialization.
• Investors should watch gross margin, operating cash burn and the updated cash balance when SenesTech reports complete third-quarter results during the week of November 9.